Atrial Fibrillation in Active Cancer Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Caen
About this trial
Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guidelines. The objective of this study is to create a prospective multicenter international registry of adult patients with an active cancer and experiencing atrial fibrillation to study major cardiovascular events occurrence during a 1 year follow-up.
Eligibility criteria
Qualifiers
adult patients
outpatients or hospitalized patients
with a confirmed cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor, known intracerebral metastases, or acute leukemia) and an active cancer (defined as cancer that had been diagnosed within the past 6 months or recurrent locally advanced or metastatic cancer, for which anticancer treatment was being given at the time of enrollment or during 6 months before enrollment)
at least 1 episode of atrial fibrillation (new onset AF occuring after cancer diagnosis or history of paroxysmal of persistant AF prior to cancer diagnosis and an AF recurrence after cancer diagnosis)
Disqualifiers
patient with palliative cares or other conditions resulting in short term death (death expected in the month following atrial fibrillation occurrence)
history of long-standing persistant or permanent AF prior to cancer diagnosis
Trial design
Treatments tested in this trial
- occurence of atrial fibrillation
Treatment groups
No treatment groups listed
Sponsors and collaborators
University Hospital, Caen
Lead sponsor
University Hospital, Marseille, France
Collaborator
Hospices Civils de Lyon, France
Collaborator
Centre Francois Baclesse, Caen, France
Collaborator
University Hospital of Saint-Etienne, France
Collaborator
Hôpital Lariboisière Fernand Widal, Paris, France
Collaborator
Institut de Cancérologie de l'Ouest Nantes, France
Collaborator
Fundacion Cardio Onco, Santiago, Chile
Collaborator
University of Newcastle, Australia
Collaborator
University Hospital, Rouen
Collaborator
Source ClinicalTrials.gov